HRMY Harmony Biosciences Holdings, Inc. Company Cash Volume

Wakix sales are generating a powerful cash flow, although the market has already priced this growth into the quotes. The volume of physical cash demonstrates the business's liquidity, where the current parameter equals 0.77. Harmony Biosciences (HRMY) relies on its financial stability through insurance reimbursements for narcolepsy therapy, while risk mitigation is driven by the expansion of clinical trials for treating rare nervous system pathologies.
Harmony Biosciences Holdings, Inc. (HRMY) - metric breakdowns and financial figures

This metric measures the volume of liquid assets, determining the issuer's ability to cover operating expenses and invest in growth without incurring external debt. By analyzing the cash dynamics of Harmony Biosciences (HRMY), an investor assesses the company's margin of safety to protect its market share in the insomnia drug segment in the face of upcoming competition from new therapeutic analogs.